Bristol Myers, Cellares sign global CAR-T deal as biopharma companies look to
- Bristol Myers, Cellares sign global CAR-T deal as biopharma companies look to diversify manufacturing partners Endpoints News
- Bristol Myers signs $380 mln CAR-T therapies supply deal with Cellares Reuters
- With $380M deal, Bristol Myers Squibb ups the ante with cell therapy manufacturer Cellares FiercePharma
- BMS Taps Cellares in $380M CAR-T Cell Therapy Manufacturing Agreement BioSpace
- Bristol Myers Squibb and Cellares Announce a $380M Worldwide Capacity Reservation and Supply Agreement for the Manufacture of CAR T Cell Therapies to Bring the Promise of Cell Therapy to More Patients, Faster Yahoo Finance
Read More: Bristol Myers, Cellares sign global CAR-T deal as biopharma companies look to